Vectus Taps Pulmonary Fibrosis Expert as VB0004 Trial Plans Advance
VBS: $0.076 +8.57% · MC: $4M
Vectus Biosystems has appointed Professor Tamera Corte, a pulmonary fibrosis specialist and experienced clinical-trial investigator, as Chief Clinical Advisor to guide development of its lead candidate VB0004. The appointment supports preparations for a planned adaptive Phase Ib/IIa trial in idiopathic pulmonary fibrosis; FDA written feedback on the proposed programme is expected by mid-November and is intended to inform the next clinical and regulatory steps.

Comments